| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 25 | NL 4 | 99.59 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 69 | NL 7 | 99.73 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 38 | NL 2 | 99.32 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 226 | NL 19 | 99.36 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 146 | NL 6 | 99.22 |
| Blood properties and coagulation | Lifetime | 148 | NL 6 | 98.25 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 63 | NL 5 | 98.25 |
| Platelet Disorders and Treatments | Lifetime | 261 | NL 15 | 98.28 |
| Sepsis Diagnosis and Treatment | Lifetime | 538 | NL 30 | 97.74 |
| Hemophilia Treatment and Research | Lifetime | 215 | NL 21 | 97.36 |
| Acute Myocardial Infarction Research | Lifetime | 897 | NL 46 | 97.40 |
| Trauma, Hemostasis, Coagulopathy, Resuscitation | Lifetime | 345 | NL 9 | 96.30 |
| Vitamin K Research Studies | Lifetime | 184 | NL 14 | 94.43 |
| Protease and Inhibitor Mechanisms | Lifetime | 934 | NL 29 | 95.22 |
| Diagnosis and Treatment of Venous Diseases | Lifetime | 733 | NL 34 | 92.14 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 82 | NL 6 | 98.90 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 105 | NL 2 | 97.25 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 32 | NL 2 | 95.20 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 475 | NL 29 | 96.62 |
| Platelet Disorders and Treatments | 2021-2025 | 243 | NL 20 | 92.84 |
| Acute Myocardial Infarction Research | 2021-2025 | 597 | NL 26 | 93.26 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 264 | NL 10 | 89.56 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 215 | NL 20 | 87.79 |
| Peripheral Artery Disease Management | 2021-2025 | 722 | NL 23 | 86.17 |
| Blood properties and coagulation | 2021-2025 | 162 | NL 5 | 84.44 |
| Diagnosis and Treatment of Venous Diseases | 2021-2025 | 377 | NL 9 | 81.16 |
| Vitamin K Research Studies | 2021-2025 | 102 | NL 5 | 74.71 |